Lene Ryom1, Jens D Lundgren1, Mike Ross2, Ole Kirk1, Matthew Law3, Philippe Morlat4, Eric Fontas5, Colette Smit6, Christoph A Fux7, Camilla I Hatleberg1, Stéphane de Wit8, Caroline A Sabin9, Amanda Mocroft9. 1. Department of Infectious Diseases, CHIP, Section 2100, Rigshospitalet, University of Copenhagen, Denmark. 2. Division of Nephrology, Mount Sinai School of Medicine, New York. 3. Kirby Institute, University of New South Wales, Sydney, Australia. 4. Université Bordeaux, INSERM U 897, CHU de Bordeaux. 5. Nephrology Department, Public Health Department, CHU Nice, France. 6. Academic Medical Center, Division of Infectious Diseases Department of Global Health, University of Amsterdam HIV Monitoring Foundation, Amsterdam, The Netherlands. 7. Clinic for Infectious Diseases and Hospital Hygiene, Kantonsspital Aarau, Switzerland. 8. Department of Infectious Diseases, CHU Saint-Pierre, Brussels, Belgium. 9. Research Department of Infection and Population Health, University College London, United Kingdom.
Abstract
BACKGROUND: While the association between renal impairment and cardiovascular disease (CVD) is well established in the general population, the association remains poorly understood in human immunodeficiency virus (HIV)-positive individuals. METHODS: Individuals with ≥2 estimated glomerular filtration rate (eGFR) measurements after 1 February 2004 were followed until CVD, death, last visit plus 6 months, or 1 February 2015. CVD was defined as the occurrence of centrally validated myocardial infarction, stroke, invasive cardiovascular procedures, or sudden cardiac death. RESULTS: During a median follow-up duration of 8.0 years (interquartile range, 5.4-8.9 years) 1357 of 35 357 individuals developed CVD (incidence rate, 5.2 cases/1000 person-years [95% confidence interval {CI}, 5.0-5.5]). Confirmed baseline eGFR and CVD were closely related with 1.8% of individuals (95% CI, 1.6%-2.0%) with an eGFR > 90 mL/minute/1.73 m(2) estimated to develop CVD at 5 years, increasing to 21.1% (95% CI, 6.6%-35.6%) among those with an eGFR ≤ 30 mL/minute/1.73 m(2) The strong univariate relationship between low current eGFR and CVD was primarily explained by increasing age in adjusted analyses, although all eGFRs ≤ 80 mL/minute/1.73 m(2) remained associated with 30%-40% increased CVD rates, and particularly high CVD rates among individuals with an eGFR ≤ 30 mL/minute/1.73 m(2) (incidence rate ratio, 3.08 [95% CI, 2.04-4.65]). CONCLUSIONS: Among HIV-positive individuals in a large contemporary cohort, a strong relation between confirmed impaired eGFR and CVD was observed. This finding highlights the need for renal preventive measures and intensified monitoring for emerging CVD, particularly in older individuals with continuously low eGFRs.
BACKGROUND: While the association between renal impairment and cardiovascular disease (CVD) is well established in the general population, the association remains poorly understood in human immunodeficiency virus (HIV)-positive individuals. METHODS: Individuals with ≥2 estimated glomerular filtration rate (eGFR) measurements after 1 February 2004 were followed until CVD, death, last visit plus 6 months, or 1 February 2015. CVD was defined as the occurrence of centrally validated myocardial infarction, stroke, invasive cardiovascular procedures, or sudden cardiac death. RESULTS: During a median follow-up duration of 8.0 years (interquartile range, 5.4-8.9 years) 1357 of 35 357 individuals developed CVD (incidence rate, 5.2 cases/1000 person-years [95% confidence interval {CI}, 5.0-5.5]). Confirmed baseline eGFR and CVD were closely related with 1.8% of individuals (95% CI, 1.6%-2.0%) with an eGFR > 90 mL/minute/1.73 m(2) estimated to develop CVD at 5 years, increasing to 21.1% (95% CI, 6.6%-35.6%) among those with an eGFR ≤ 30 mL/minute/1.73 m(2) The strong univariate relationship between low current eGFR and CVD was primarily explained by increasing age in adjusted analyses, although all eGFRs ≤ 80 mL/minute/1.73 m(2) remained associated with 30%-40% increased CVD rates, and particularly high CVD rates among individuals with an eGFR ≤ 30 mL/minute/1.73 m(2) (incidence rate ratio, 3.08 [95% CI, 2.04-4.65]). CONCLUSIONS: Among HIV-positive individuals in a large contemporary cohort, a strong relation between confirmed impaired eGFR and CVD was observed. This finding highlights the need for renal preventive measures and intensified monitoring for emerging CVD, particularly in older individuals with continuously low eGFRs.
Authors: Saskia M E Vrouenraets; Christoph A Fux; Ferdinand W N M Wit; Evian Fernandez Garcia; Kees Brinkman; Frans J Hoek; Jan P van Straalen; Hansjakob Furrer; Ray T Krediet; Peter Reiss Journal: Clin Nephrol Date: 2012-04 Impact factor: 0.975
Authors: Vasantha Jotwani; Rebecca Scherzer; Andy Choi; Lynda Szczech; Joseph F Polak; Richard A Kronmal; Carl Grunfeld; Michael Shlipak Journal: Am J Nephrol Date: 2011-04-21 Impact factor: 3.754
Authors: Brenda R Hemmelgarn; Braden J Manns; Anita Lloyd; Matthew T James; Scott Klarenbach; Robert R Quinn; Natasha Wiebe; Marcello Tonelli Journal: JAMA Date: 2010-02-03 Impact factor: 56.272
Authors: Elizabeth George; Gregory M Lucas; Girish N Nadkarni; Derek M Fine; Richard Moore; Mohamed G Atta Journal: AIDS Date: 2010-01-28 Impact factor: 4.177
Authors: Ralph B D'Agostino; Ramachandran S Vasan; Michael J Pencina; Philip A Wolf; Mark Cobain; Joseph M Massaro; William B Kannel Journal: Circulation Date: 2008-01-22 Impact factor: 29.690
Authors: A Natali; B Boldrini; S Baldi; M Rossi; P Landi; S Severi; A Solini; E Ferrannini Journal: Nutr Metab Cardiovasc Dis Date: 2013-12-24 Impact factor: 4.222
Authors: Andy I Choi; Yongmei Li; Steven G Deeks; Carl Grunfeld; Paul A Volberding; Michael G Shlipak Journal: Circulation Date: 2010-01-25 Impact factor: 29.690
Authors: Sarah Chwiki; Maria Mercedes Campos; Mary E McLaughlin; David E Kleiner; Joseph A Kovacs; Caryn G Morse; Mones S Abu-Asab Journal: Ultrastruct Pathol Date: 2017-02-28 Impact factor: 1.094
Authors: Lediya T Cheru; Kathleen V Fitch; Charles F Saylor; Michael Lu; Udo Hoffmann; Janet Lo; Steven K Grinspoon Journal: AIDS Date: 2019-02-01 Impact factor: 4.177
Authors: C I Hatleberg; L Ryom; A d'Arminio Monforte; E Fontas; P Reiss; O Kirk; W El-Sadr; A Phillips; S de Wit; F Dabis; R Weber; M Law; J D Lundgren; C Sabin Journal: HIV Med Date: 2018-07-18 Impact factor: 3.180
Authors: James H Stein; Noah Kime; Claudia E Korcarz; Heather Ribaudo; Judith S Currier; Joseph C Delaney Journal: Arterioscler Thromb Vasc Biol Date: 2020-12-17 Impact factor: 8.311
Authors: Violeta J Rodriguez; John M Abbamonte; Manasi S Parrish; Deborah L Jones; Stephen Weiss; Suresh Pallikkuth; Michal Toborek; Maria L Alcaide; Dushyantha Jayaweera; Savita Pahwa; Tatjana Rundek; Barry E Hurwitz; Mahendra Kumar Journal: Int J STD AIDS Date: 2021-11-02 Impact factor: 1.456
Authors: Carmine Rossi; Sahar Saeed; Joseph Cox; Marie-Louise Vachon; Valérie Martel-Laferrière; Sharon L Walmsley; Curtis Cooper; M John Gill; Mark Hull; Erica E M Moodie; Marina B Klein Journal: AIDS Date: 2018-03-27 Impact factor: 4.177